SOURCE: Kelyniam Global, Inc.

Kelyniam Global, Inc.

April 27, 2011 16:00 ET

Kelyniam Engages Pharmexsys to Support Commercial Launch

CANTON, CT--(Marketwire - Apr 27, 2011) - Kelyniam Global, Inc. (PINKSHEETS: KLYG), an emerging medical device company, announced today that it has engaged Pharmexsys, LLC to support the launch of their recently approved patient specific custom cranial implant. Pharmexsys is a consulting firm that specializes in helping early stage life science companies design and develop the business systems and infrastructure required to manage rapid growth.

"We selected Pharmexsys because of their focus on the life science space and the breadth of their experience across many operational functions within a business," said James Ketner, President and CEO of Kelyniam Global. "Engaging Pharmexsys will accelerate the launch of our first product and ensure that our internal systems are robust and able to manage the strong demand for the product."

The Kelyniam Custom Skull Implants (CSI) are designed and manufactured for each individual patient to correct or replace bony voids in the cranial skeleton caused by trauma or birth defects. The company received FDA clearance to market their custom cranial implant made from PEEK-OPTIMA® earlier this month. Streamlined CAD/CAM design and manufacturing techniques will enable Kelyniam to deliver patient specific implants within 24 hours of receiving an order.

"I am pleased to be working with an innovative and customer focused company like Kelyniam," said Ross Bjella, Pharmexsys' President. "Our experience working with rapidly growing life science companies makes Pharmexsys uniquely capable of designing the infrastructure and implementing the business processes required to meet Kelyniam's demanding needs."

Kelyniam is planning to launch the CSI product through independent sales representatives early third quarter this year.

About Pharmexsys, LLC:

Pharmexsys, LLC is a consulting firm focused on the unique needs of small and mid-tier life science and B2B healthcare service companies. Founder Ross Bjella is a proven life science executive with deep experience in management, B2B business services, strategy development, product and corporate branding and positioning, new product launches, 3PL selection, supply chain efficiency and contract negotiations. In 2009, PharmaVoice magazine named Ross one of the Top 100 Most Inspiring People in Pharmaceuticals. Ross is an advisor to the Wisconsin Early Stage Fund and has advised multiple early stage companies and was a two time regional finalist in Ernst & Young's Entrepreneur of the Year program. To learn more, go to

About Kelyniam Global, Incorporated:

Kelyniam Global, Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at for more information.

Forward-Looking Statements
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

Contact Information